Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel

Grau, Juan J.; Caballero, Miguel; Campayo, Marc; Jansà, Sonia; Vargas, Mauricio; Alós, Llúcia; Monzó, Mariano

doi:10.1002/lary.20254

Cited by 18 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study populations of previous publications were mostly hospital-based and ranged from 47 to 531 HNC cases [10, 13]. Further, the present study population included 922 White cases and 305 African Americans cases which allowed for estimation of race-specific HRs.…”

Section: Discussionmentioning

confidence: 99%

Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival

Wyss

Weissler

Avery

et al. 2014

Cancer Causes Control

View full text Add to dashboard Cite

Purpose Head and neck cancers (HNC) are commonly treated with radiation and platinum-based chemotherapy, which produce bulky DNA adducts to eradicate cancerous cells. Because nucleotide excision repair (NER) enzymes remove adducts, variants in NER genes may be associated with survival among HNC cases both independently and jointly with treatment. Methods Cox proportional hazards models were used to estimate race-stratified (White, African American) hazard ratios (HRs) and 95 % confidence intervals for overall (OS) and disease-specific (DS) survival based on treatment (combinations of surgery, radiation, and chemotherapy) and 84 single nucleotide polymorphisms (SNPs) in 15 NER genes among 1,227 HNC cases from the Carolina Head and Neck Cancer Epidemiology Study. Results None of the NER variants evaluated were associated with survival at a Bonferroni-corrected alpha of 0.0006. However, rs3136038 [OS HR = 0.79 (0.65, 0.97), DS HR = 0.69 (0.51, 0.93)] and rs3136130 [OS HR = 0.78 (0.64, 0.96), DS HR = 0.68 (0.50, 0.92)] of ERCC4 and rs50871 [OS HR = 0.80 (0.64, 1.00), DS HR = 0.67 (0.48, 0.92)] of ERCC2 among Whites, and rs2607755 [OS HR = 0.62 (0.45, 0.86), DS HR = 0.51 (0.30, 0.86)] of XPC among African Americans were suggestively associated with survival at an uncorrected alpha of 0.05. Three SNP-treatment joint effects showed possible departures from additivity among Whites. Conclusions Our study, a large and extensive evaluation of SNPs in NER genes and HNC survival, identified mostly null associations, though a few variants were suggestively associated with survival and potentially interacted additively with treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival

Wyss

Weissler

Avery

et al. 2014

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…The literature search yielded 58 publications. The following studies were excluded: two were published in Chinese(Yang et al, 2008b, Wen et al, 2007) and one in Polish(Rusin et al, 2008); three did not report gene polymorphisms(Cheng et al, 2002, Wei et al, 2005, Yang et al, 2006); two assessed the association between gene polymorphisms and survival(Grau et al, 2009, Handra-Luca et al, 2007); seven evaluated treatment efficacy(Bozec et al, 2007, Carles et al, 2006, Fountzilas et al, 2009, Jun et al, 2008, Kornguth et al, 2005, Quintela-Fandino et al, 2006, Werbrouck et al, 2009); one assessed the potential of gene polymorphisms as predictive and prognostic markers(Koh et al, 2009); two studies were conducted in patients only(Geisler et al, 2005, Hsieh et al, 2003); one study evaluated the potential of gene polymorphisms as risk modifiers of the association of oral contraceptives and oral cancer risk(Applebaum et al, 2009); one did not evaluate the genes of interest(Gajecka et al, 2005a); three studies evaluated the risk of oral leukoplakia(Majumder et al, 2009, Wang et al, 2007, Yang et al, 2008a); two studies evaluated the risk of secondary primary neoplasms(Gal et al, 2005); two reported on haplotypes only(Michiels et al, 2007, Majumder et al, 2009) and one included lung cancer under upper-aerodigestive tract (UADT) cancer(Buch et al, 2005). Therefore, 30 studies that included 19,343 individuals (7,291 cases and 12,052 controls) were considered for the meta-analysis.…”

Section: Methodsmentioning

confidence: 99%

Polymorphisms in DNA damage response genes and head and neck cancer risk

2010

View full text Add to dashboard Cite

Context Polymorphisms in DNA repair genes have been reported contributing factors in head and neck cancer risk but studies have shown conflicting results. Objective To clarify the impact of DNA repair gene polymorphisms in head and neck cancer risk. Method A meta-analysis including 30 case-control studies was performed. Results Marginally statistically significant association was found for XRCC1 codon 399 (for Caucasians only), XPD Asp312Asn and XRCC1 codon 194 variants and head and neck cancer. Conclusion Assessments of the effects of smoking, alcohol, HPV and race/ethnicity on the association between DNA repair gene polymorphisms and head and neck cancer are needed.

show abstract

“…observed a poorer response in these patients [54]. The association with efficacy of paclitaxel treatment is somewhat less clear; ABCB1 variant alleles have been associated with shorter progression-free survival, overall survival and lower disease control rates in Koreans [51,55], but greater response rate [56,57] and progression-free survival [58] in other populations.…”

Section: Pharmacogeneticsmentioning

confidence: 99%

Pharmacogenetics, Enzyme Probes and Therapeutic drug Monitoring as Potential Tools for Individualizing Taxane Therapy

2013

View full text Add to dashboard Cite

The taxanes are a class of chemotherapeutic agents that are widely used in the treatment of various solid tumors. Although taxanes are highly effective in cancer treatment, their use is associated with serious complications attributable to large interindividual variability in pharmacokinetics and a narrow therapeutic window. Unpredictable toxicity occurrence necessitates close patient monitoring while on therapy and adverse effects frequently require decreasing, delaying or even discontinuing taxane treatment. Currently, taxane dosing is based primarily on body surface area, ignoring other factors that are known to dictate variability in pharmacokinetics or outcome. This article discusses three potential strategies for individualizing taxane treatment based on patient information that can be collected before or during care. The clinical implementation of pharmacogenetics, enzyme probes or therapeutic drug monitoring could enable clinicians to personalize taxane treatment to enhance efficacy and/or limit toxicity.

show abstract

Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel

Abstract: Response rate and OS were significantly higher in patients with two or more accumulated SNPs.

Cited by 18 publications

References 21 publications

Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival

Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival

Polymorphisms in DNA damage response genes and head and neck cancer risk

Pharmacogenetics, Enzyme Probes and Therapeutic drug Monitoring as Potential Tools for Individualizing Taxane Therapy

Contact Info

Product

Resources

About